Progress and Prospect of Nanocarriers: Design, Concept, and Recent Advances

Progress and Prospect of Nanocarriers: Design, Concept, and Recent Advances examines the different nanocarriers that are currently being developed for specific applications in biomedical drug delivery, disease management, diagnosis and therapy. Nanosized drug delivery systems have gained tremendous amounts of clinical interest due to their effective bio-distribution and enhanced pharmacokinetic and selective targeting capability which results in high therapeutic potential, low side effects, and the generation of cost-effective drug delivery systems. Numerous effective nanocarriers have been evolving, including polymeric nanoparticles, liposomes, microspheres, dendrimers, and carbon nanotubes.This book is a helpful reference for scientists and students in the fields of drug delivery, biomaterials and nanomedicine, as well as scientists and engineers in industrial disciplines of drug delivery and drug formulation.

Dr. Sushil K. Kashaw is an Associate Professor in the Department of Pharmaceutical Sciences and his Integrated Drug Discovery Research Laboratory is focused to develop new molecules for the treatment of cancer, tuberculosis, malaria and other life threatening diseases. He has completed his Raman Postdoctoral Research from Wayne State University, Detroit, USA in 2016. To his credit he has 110 high impact research publications, six books, six book chapters, one granted and two filed patent. Dr. Kashaw has completed five research projects sponsored by SERB, UGC, MPCST. His total citations are 3919, h-index 28 and i10 of 49. He has been conferred with many prestigious awards/fellowships like Raman Postdoctoral Fellowship, Outstanding Oral Presentat ion Award from APP, Young Scientist Award by APP, Best Teacher Award in Pharm. Chemistry by APTI, M.P. branch, Research Excellence Award by Institute of Scholars, Best Researcher and Pharma recognition award by Nirali Publication in association with APTI and thirty five awards as co-author at various scientific platforms. He has delivered 42 invited lectures, chaired 28 scientific sessions, presented 40 papers in the conferences and developed 10 e-contents for CEC-MHRD. Apart from his academic credentials Dr. Kashaw is actively contributing in the holistic development of the university. Currently he is the Member of the Executive Council and former Member of Academic Council of the university. He has organized several conferences and training programmes for students and teachers. Dr. Kashaw has supervised five PhD and forty nine M. Pharm students. His area of research is molecular modeling, medicinal chemistry and nanotechnology.

Dr. Samaresh Sau is an Assistant Professor (Research) in the Department of Pharmaceutical Sciences atWayne State University, Detroit, MI. In addition, Dr. Sau is an affiliate Member Molecular Therapeutics (MT) Program at Barbara Ann Karmanos Cancer Institute. For more than 11 years, Dr. Sau has been developing potent biomarker-targeted nanoparticles, small molecules, and antibody-drug conjugates for the therapeutic benefit of cancer. Dr. Sau completed his Ph.D. from India’s premier research Institute, CSIR-Indian Institute of Chemical Technology (CSIR-IICT), Hyderabad, India. Then,he undertook his first postdoctoral fellowship in the Department of Chemistry at Purdue University to work with Prof. Philip S. Low, a pioneer of biomarker-targeted drug development. Working with Prof. Low and his company (Endocyte acquired by Novartis), he has been exposed and master-skilled to the process of developing clinically translatable biomarker-targeted therapeutics of cancers. Dr. Sau is the author of about 50 publications, 4 book chapters, and inventor of 2-pending patent applications. In addition, Dr. Sau is the Co-I/PI of the department of defense (DoD), National Institute of Health (NIH), and Michigan State Technology Commercialization (MTRAC) and Burroughs Wellcome Fund (BWF)-CRTG grant funding. Dr. Sau’s future research objective is to develop potent targeted therapeutic and diagnostic agents for clinical translation in cancer.

Dr. Iyer is the Director of Use-inspired Biomaterials and Integrated Nano Delivery (U-BiND) Systems Laboratory and an Associate Professor with Tenure in the Department of Pharmaceutical Sciences at Wayne State University in Detroit, Michigan, USA. He also serves as a Scientific Member of the Molecular Imaging Program (MIP) at the Barbara Ann Karmanos Cancer Institute in Detroit, Michigan, USA. Dr. Iyer received his PhD in 2008, in Polymer Engineering, under the mentorship of world-renowned scientist and 2016 Nobel Prize in Chemistry Nominee, Prof. Hiroshi Maeda at Sojo University in Kumamoto, Japan. Dr. Iyer was the recipient of the Controlled Release Society’s (CRS) T. Nagai Research Achievement Award in 2012. Dr. Iyer completed his postdoctoral training in Cancer Radiology at the University of California, San Francisco (UCSF) in California, USA. In 2018 Dr. Iyer received an Early Career Investigator Award from the US Department of Defense (DoD). Dr. Iyer has authored more than 100 publications in peer reviewed International Journals (H-index:45), and books of high repute. He has more than 200 scientific presentations and invited talks at International Conferences and Workshops. He has five patents issued/pending. His areas of research are broadly focused on designing use-inspired bio- and nano-medical technologies aimed towards clinical translation using biocompatible delivery systems that have enhanced disease targeting with reduced toxicity burden to patients. He has wide expertise in biomaterials and nanomedicine, polymer chemistry and formulation development, drug and gene delivery systems, molecular and functional imaging, micro and nanoparticles for treating diseases such as infection,cancerand age-related dementia. His laboratory is funded by agencies such as National Institutes of Health and the US Department of Defense.